Relevance to the development of science or a scientific field
Pomembnost za razvoj znanosti ali znanstvenega področja 
-------------------------------------------------------------

**Odkrivanje novih biomarkerjev je ključnega pomena za napredek in natančnost personalizirane medicine. Omogoča natančen in usmerjen pristop k prilagajanju terapije na način, ki bo zagotovil najboljši odziv, najvišjo raven varnosti in s tem boljšo oskrbo pacientov.** Večina, če ne celo vse sodobne znanstvene metode, vključno z odkrivanjem biomarkerjev, danes temeljijo na podatkih. Vsa ta ogromna skladišča genomskih podatkov in nastajajoče odprte baze podatkov z rezultati kliničnih preskušanj lahko učinkovito obdelamo in rudarimo zgolj s pomočjo računskih tehnik. Velik izziv predstavlja iskanje pristopa, v katerega so učinkovito vključeni domenski eksperti. Modeli črnih skrinjic se v medicini niso nikoli prijeli. Biomedicinski modeli, katerih mehanike in rezultatov ni mogoče poglobljeno razumeti, namreč v praksi nikoli niso uporabljeni.

**Predlagani projekt bo prispeval k znanosti na presečišču računalniških pristopov k molekularni biologiji, predstavitvi rezultatov podatkovnega rudarjenja in modeliranja ter interakciji med človekom in računalnikom.** Z orodji, ki integrirajo podatke z obstoječim znanjem iz javnih podatkovnih zbirk ter rezultate predstavijo v interaktivnem, vizualnem okolju, želimo izboljšati pristope k odkrivanju biomarkerjev in širše odpreti to področje. Predlagane metode naslavljajo integracijo podatkov, vizualno analitiko in raziskave v hevrističnih, na znanju temelječih pristopih k optimizaciji. Te teme so dandanes v središču raziskovanja umetne inteligence. Razvoj naprednih tehnologij v obliki praktičnih in intuitivnih računalniških orodij za obdelavo podatkov o preživetju je ključnega pomena za napredek znanosti. Trdno smo prepričani, da lahko predlagani projekt v tem pogledu pomembno prispeva.


**Discovery of new biomarkers is crucial to advance personalized medicine and its precision and targeted approach to tailor therapy with the best response and highest safety margin to ensure better patient care.** Most, if not all, modern scientific methods, including biomarker discovery, are becoming data-driven. Vast repositories of genomic data and emerging open databases with clinical trial results call for computational techniques to mine them. But they are also challenging us to find the approaches which can actively engage domain experts. Namely, black-box models never took root in medicine, and without a deep understanding of mechanics and results, no biomedical model was ever applied in practice.

**The proposed project will advance the science at the intersection of computational approaches to molecular biology, presentation of results of mining and modeling, and human-computer interaction.** By proposing tools that integrate data and knowledge and showcase the results in an interactive, visual environment, we aim to open-up the approaches to biomarker discovery and democratize the field. Our proposed methods address data integration, visual analytics, and research in the heuristic, knowledge-driven approaches to optimization, the topics currently at the spotlight of artificial intelligence research. And finally, the development of enabling technologies in the form of practical and intuitive computational toolboxes to handle survival data is essential for the advancement of science. We firmly believe the proposed project can make significant contributions in this respect.




Direct impact of the project for the economy and society
--------------------------------------------------------
Odkrivanje biomarkerjev je počasen, naporen in drag postopek, ki zahteva multidisciplinarno ekipo statistikov, podatkovnih znanstvenikov, farmakologov, zdravnikov in regulatorjev javnega zdravja. Orodja, predlagana v tem projektu, bodo **pomembno preobrazila komunikacijo med deležniki, saj bodo omogočila interaktivno postavljanje hipotez v realnem času** in, v določeni meri, tudi vrednotenje hipotez. Sodelujoče podjetje Genialis na podlagi lastnih izkušenj ve, kako težko je pojasniti in utemeljiti izbiro genskega sklopa zdravstvenim organom - v primeru Genialisa, FDA -  in diagnostičnim podjetjem. Predlagani interaktivni vizualni moduli predstavljajo ključno inovacijo.

Predlagani načini integracije javnih podatkovnih baz v samodejno interpretacijo odkritih vzorcev predstavljajo pomemben korak v smeri **na podatkih temelječih znanstvenih odkritij**, ki vztrajno nadomešča tradicionalni ekspertni pristop. Vključevanje številnih domenskih strokovnjakov v vseh fazah postopka odkrivanja biomarkerjev je glavno ozko grlo, ki ga želimo s predlaganimi orodji zaobiti, in tako ponuditi rešitve številnim zainteresiranim stranem, od akademskih laboratorijev in univerzitetnih zdravstvenih centrov do biofarmacevtskih podjetij.

Predlagamo **razvoj računalniških orodij, ki bodo podpirala mnogo hitrejši razvoj znanstvenih odkritij**. To bo povzročilo zmanjšanje stroškov razvoja in registracije novih biomarkerjev, kar je zanimiv cilj za v projektu sodelujoče podjetje Genialis. Ker gre za odprta orodja, ki bodo slednjič na voljo v okviru permisivne licence tako akademskim krogom kot gospodarstvu, pričakujemo široko uporabo razvitih metod. Načrtovane dejavnosti distribucije orodij in znanj, ki vključujejo video posnetke na YouTubu in praktična navodila, bodo novince še dodatno opolnomočile pri odkrivanju biomarkerjev in Genialisu zagotovile dodatno promocijo in prepoznavnost.


Biomarker discovery is a slow, laborious, and costly process that involves a multidisciplinary team of statisticians, data scientists, pharmacologists, physicians, and public health regulators. The tools proposed in this project will **radically change the communication between stakeholders, as they will allow interactive and real-time hypotheses generation** and, to an extent, hypotheses evaluation. The participating SME Genialis has a first-hand experience of how difficult it is to explain and justify gene set selection to health authorities – in Genialis' case, the FDA – and diagnostic companies. We see the proposed interactive visual modules as a crucial innovation.

The proposed methods of integrating the public knowledge bases into the automatic interpretation of discovered patterns present a big step towards **data-driven discovery** and are steadily replacing traditional expert-driven discovery. Involving many domain experts used to be crucial at the identification stage of the biomarker discovery process. Data-driven approaches circumvent this bottleneck and democratize access to the hypothesis generation capabilities to many interested parties, from academic labs and university medical centers to biopharma companies.

We propose to develop computational tools to support **much faster rate of scientific discovery**. Very directly, this means reduced costs of development and registration of novel biomarkers, which is an appealing goal for the participating SME. Since the tools will be open-sourced and made available under a permissive license to academia and the industry alike, we envision a wide adoption of the developed methods. The planned dissemination activities, which include YouTube videos and hands-on tutorials, will further empower newcomers into biomarker discovery and provide extra promotion and visibility for Genialis.

Indirect impact of the project for society
------------------------------------------
Reševanje problema odkrivanja biomarkerjev na podlagi podatkov lahko močno vpliva na številna področja medicine, zlasti na onkologijo. Rak pomembno vpliva na globalno družbo. Čeprav so bila v zadnjih letih razvita številna učinkovita in inovativna zdravljenja, običajno dobro delujejo le pri majhnem delu bolnikov. Zaradi tega nova zdravila pogosto ne uspejo pravočasno doseči pravih bolnikov. Potrebujemo nove biomarkerje, ki natančno zajemajo pacientovo fiziološko stanje v času odločitve za zdravljenje. To vsaj obljublja personalizirana medicina in orodja, razvita v tem projektu, predstavljajo pomemben mejnik na poti k izpolnitvi obljube. Katere vrste zdravljena so na voljo pacientom, je odvisno od številnih spremenljivk, predvsem od časa (rak je smrtonosen) in denarja (politike zasebnih in javnih zavarovalnic). Personalizirana medicina pomaga rešiti oboje.

Novi biomarkerji pomenijo natančno in pravočasno izvajanje zdravljenja, kar pa pomeni podaljšano pričakovano življenjsko dobo in dobrobit bolnikov v naši starajoči se družbi. Pričakovani so tudi nižji stroški zdravljenja in krajše čakalne vrste. Biomarkerji prihodnosti so kompleksni in personalizirani modeli bolezni, orodja, razvita v tem projektu, pa bodo pomagala ustvariti nove biomarkerje in jih predstaviti primernim deležnikom. Utemeljeno lahko pričakujemo, da bo boljši dostop do orodij za odkrivanje biomarkerjev pripomogel k nastanku novih podjetij na tem področju. Zadnje čase smo tako priča nastanku podjetij na področju molekularne diagnostike, ki se neposredno napajajo iz bazena novih biomarkerjev.



Solving the problem of data-driven biomarker discovery may profoundly impact many areas of medicine, and particularly oncology. Cancer has a significant impact on global society. While many efficient and innovative treatments have been developed in recent years, they typically work well on only a fraction of the population. For this reason, new treatments have difficulty finding the right patients in time. The world needs novel biomarkers that accurately capture the patient's physiological state at the treatment decision time. That, at least, is the promise of **precision medicine**, and the tools developed in this project will add an essential milestone on the road to delivering on this promise. What treatment therapies are made available to patients is a function of many variables, most crucially time (cancer is deadly) and money (private and public insurers' policies). Personalized medicine helps save both. 

New biomarkers mean precise and timely delivery of treatment, which in turn means **increased life expectancy and wellbeing of patients in our aging society**. Moreover, **decreased costs of treatment** and waiting lines are expected. The future biomarkers are complex and personalized models of disease, and the tools developed in this project will help create new candidates and present them to relevant stakeholders. It is not a stretch of the imagination to say that it is likely that the democratization of tools for biomarker discovery will give rise to new companies operating in this space. Finally, we are witnessing an emergence of **molecular diagnostic companies** that grow from and around these new biomarkers. 